Table 2.

Adjusted multivariable logistic regression evaluating characteristics associated with Papanicolaou (Pap) testing in 3 years following HPV vaccine series initiation (N=24,964)

	Pap test
	% received Pap test	Model 1 aOR (95% CI)	Model 2 aOR (95% CI)
Age
19–21	73.6	1.00	1.00
22–26	86.8	1.97 (1.84, 2.12)	1.90 (1.77, 2.05)
Region
Midwest	77.9	0.74 (0.69, 0.80)	0.75 (0.69, 0.81)
Northeast	71.3	0.48 (0.43, 0.52)	0.48 (0.44, 0.53)
South	83.1	1.00	1.00
West	78.0	0.75 (0.68, 0.83)	0.75 (0.68, 0.82)
Provider giving the 1st dose
Obstetrics/gynecology	86.2	1.00	1.00
Primary care provider	76.2	0.59 (0.55, 0.64)	0.66 (0.61, 0.71)
Adolescent/pediatric provider	62.8	0.38 (0.35, 0.42)	0.44 (0.40, 0.49)
Other	76.7	0.65 (0.54, 0.77)	0.69 (0.58, 0.83)
Year of the 1st dose
2006	84.4	1.51 (1.27, 1.78)	1.46 (1.23, 1.73)
2007	80.3	1.24 (1.14, 1.36)	1.25 (1.14, 1.36)
2008	79.5	1.14 (1.05, 1.25)	1.16 (1.06, 1.26)
2009	75.7	1.00	1.00
Number of doses received
1	72.2	0.60 (0.56, 0.66)	0.60 (0.55, 0.65)
2	78.4	0.81 (0.75, 0.88)	0.80 (0.74, 0.87)
3+	82.5	1.00	1.00
History of cervical dysplasia
No	76.7	–	1.00
Yes	92.3	–	2.73 (2.42, 3.09)